Business
Biophytis S A : to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in obesity
Biophytis S A : to evaluate BIO101’s potential to limit weight regain in its OBA clinical study in
About this update from Biophytis Sa
09 Sep 2026 07:00 CEST Subscribe Issuer BIOPHYTIS See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo 16165_1432691_PR__ANVISA_amendment_090926_Final.pdf Source Biophytis Provider Les Echos Company Name BIOPHYTIS ISIN FR001400OLP5 Symbol ALBPS Market Euronext Growth Company press releases subscription × To subscribe to Press releases from this issuer, visit the Subscription to Company news section in your account section or create an account . Cancel